ARTICLE | Company News

Sumitomo gains Asian rights to Poxel's diabetes candidate

November 3, 2017 6:58 PM UTC

Poxel S.A. (Euronext:POXEL) granted Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) exclusive rights to Type II diabetes candidate imeglimin (PXL008) in Japan, China, South Korea, Taiwan and nine Southeast Asian countries.

In Japan, Phase III development will be overseen by a joint steering committee. The program will consist of three studies with about 1,100 patients and is slated to begin by YE17. Sumitomo will fund the clinical program in Japan, where it will also be responsible for commercialization. Sumitomo will be responsible for development and commercialization in the other Asian countries...